Skip to content

Study · In vitro (cells) · 1987

6 results

Effect of two thymosin fraction 5 polypeptides on human peripheral blood lymphocytes.

Kokkinopoulos D, Perez S, Baxevanis C, Papamichail M

Immunopharmacology and immunotoxicology1 Jan 1987Cited by 1 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    Thymosin alpha‑1 had no effect on the tested immunological parameters of human peripheral blood lymphocytes in culture.

    In plain wordsIn cells, thymosin alpha‑1 had no effect on the tested immune measures of human blood lymphocytes.

    Outcome
    No significant changeImmunological parameters of human peripheral blood lymphocytes
    Study

    humann: not reported in source

    Human peripheral blood lymphocytes in culture
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · 24 hoursAs given in this study (human).

    Source sentences

    Summary
    In parallel experiments thymosin alpha 1 was found inactive.
    2 context sentences
    Summary · context
    Thymosin fraction 5 polypeptides beta 4 and alpha 1 were tested for their ability to affect certain immunological parameters of human peripheral blood lymphocytes (PBL).
    Summary · context
    PBL were cultured with various concentrations of the peptides for 24 hours.
  2. 02LabIn vitro (cells)Activity measurement

    In human peripheral blood lymphocytes in culture, thymosin beta‑4 significantly decreased expression of Fc alpha receptors.

    In plain wordsIn cells, thymosin beta‑4 lowered the amount of Fc alpha receptors on human blood lymphocytes.

    Outcome
    DecreaseFc alpha receptor expression on lymphocytes
    Study

    humann: not reported in source

    Human peripheral blood lymphocytes
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    various concentrations · 24 hoursAs given in this study (human).

    Source sentences

    Summary
    Thymosin beta 4 was found to induce a significant decrease in the expression of the Fc alpha receptors of PBL
    1 context sentence
    Summary · context
    PBL were cultured with various concentrations of the peptides for 24 hours.
  3. 03LabIn vitro (cells)Activity measurement

    In human peripheral blood lymphocytes in culture, thymosin beta‑4 significantly decreased the ability to express ADCC activity.

    In plain wordsIn cells, thymosin beta‑4 lowered the ability of human blood lymphocytes to show antibody dependent cell killing.

    Outcome
    DecreaseAntibody dependent cellular cytotoxic activity
    Study

    humann: not reported in source

    Human peripheral blood lymphocytes
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    various concentrations · 24 hoursAs given in this study (human).

    Source sentences

    Summary
    Thymosin beta 4 was found to induce a significant decrease in the expression of the Fc alpha receptors of PBL, as well as in their ability to express antibody dependent cellular cytotoxic (ADCC) activity.
    1 context sentence
    Summary · context
    PBL were cultured with various concentrations of the peptides for 24 hours.
  4. 04LabIn vitro (cells)Activity measurement

    Thymosin beta‑4 increased the percentage of T4 lymphocytes in cultures from normal and immunosuppressed donors.

    In plain wordsIn cells from normal and immunosuppressed donors, thymosin beta‑4 raised the share of T4 lymphocytes.

    Outcome
    IncreaseT4 lymphocyte percentage
    Study

    humann: not reported in source

    Human peripheral blood lymphocytes
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    various concentrations · 24 hoursAs given in this study (human).

    Source sentences

    Summary
    this peptide had the ability to increase the percentage of T4 lymphocytes in normal and immunosuppressed donors
    1 context sentence
    Summary · context
    PBL were cultured with various concentrations of the peptides for 24 hours.
  5. 05LabIn vitro (cells)Activity measurement

    Thymosin beta‑4 decreased the percentage of T8 positive cells in cultures from normal donors.

    In plain wordsIn cells from normal donors, thymosin beta‑4 lowered the share of T8 positive cells.

    Outcome
    DecreaseT8 positive cell percentage
    Study

    humann: not reported in source

    Human peripheral blood lymphocytes
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    various concentrations · 24 hoursAs given in this study (human).

    Source sentences

    Summary
    to decrease the percentage of T8 positive cells in normal donors.
    1 context sentence
    Summary · context
    PBL were cultured with various concentrations of the peptides for 24 hours.
  6. 06LabIn vitro (cells)Activity measurement

    Thymosin beta‑4 caused a small increase in the capacity of lymphocytes to form sheep red blood cell rosettes.

    In plain wordsIn cells, thymosin beta‑4 slightly raised the ability of human blood lymphocytes to form rosettes with sheep red blood cells.

    Outcome
    IncreaseSheep red blood cell rosette formation
    Study

    humann: not reported in source

    Human peripheral blood lymphocytes
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    various concentrations · 24 hoursAs given in this study (human).

    Source sentences

    Summary
    Finally, beta 4 peptide caused a small increase in the capacity of peripheral blood lymphocytes to form sheep red blood cell (SRBC) rosettes (ER).
    1 context sentence
    Summary · context
    PBL were cultured with various concentrations of the peptides for 24 hours.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    12 Oct 2026, 18:17 UTC

    Study data updated · source update from Europe PMC

  2. Version 3

    10 Oct 2026, 08:55 UTC

    Study results updated

  3. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  4. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.